公开(公告)号：US20230117565A1

公开(公告)日：2023-04-20

申请号：US17838769

申请日：2022-06-13

申请人： Takeda Pharmaceutical Company Limited

发明人： Stephen R. Comeau ,  Andrew Nixon ,  Niksa Kastrapeli ,  Jon A. Kenniston ,  Gregory P. Conley ,  Shauna Mason ,  Allison P. Lindberg ,  Kristopher Kopacz ,  Burt Adelman

IPC分类号： C07K16/40 ,  C07K16/36 ,  A61P7/02 ,  A61K39/395 ,  C12N9/64

摘要： Described herein are bispecific antibodies that bind to plasma kallikrein (pKal) and Factor XII and methods of producing and using such bi-specific antibodies for treating diseases or disorders associated with the contact system, e.g., hereditary angioedema or thrombosis.

公开(公告)号：US20230117295A1

公开(公告)日：2023-04-20

申请号：US18075853

申请日：2022-12-06

申请人： TAKEDA PHARMACEUTICAL COMPANY LIMITED

发明人： Koji ONO ,  Masahiro ITO ,  Toshio TANAKA ,  Moriteru ASANO ,  Takaharu HIRAYAMA ,  Jun FUJIMOTO ,  Nobuki SAKAUCHI ,  Yasuhiro HIRATA ,  Akinori TOITA ,  Nao MORISHITA ,  Hironori KOKUBO ,  Yasuhiro IMAEDA ,  Hironobu MAEZAKI ,  Douglas Robert CARY ,  Ryo MIZOJIRI ,  Nobuo CHO ,  Hiroshi BANNO ,  Hidekazu TOKUHARA ,  Yasuyoshi ARIKAWA

IPC分类号： C07D401/14 ,  C07D403/14 ,  C07D401/12 ,  C07D471/10 ,  C07D495/10 ,  C07D405/12 ,  C07D403/12 ,  C07D213/84 ,  C07D487/10 ,  C07D405/14 ,  A61P35/00

摘要： Provided is a compound that may have a superior CDK12 inhibitory action and is expected to be useful as a prophylactic or therapeutic drug for cancer and the like. A compound represented by the following formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof.

公开(公告)号：US20230112931A1

公开(公告)日：2023-04-13

申请号：US17842999

申请日：2022-06-17

申请人： Takeda Pharmaceutical Company Limited

发明人： Daniel J. Sexton ,  Malini Viswanathan

IPC分类号： C07K16/40 ,  G01N33/573

摘要： Plasma kallikrein binding proteins and methods of using such proteins are described.

公开(公告)号：US20230096592A1

公开(公告)日：2023-03-30

申请号：US17904153

申请日：2021-02-24

申请人： TAKEDA PHARMACEUTICAL COMPANY LIMITED

发明人： Jean-Baptiste Farcet ,  Juergen Siekmann

IPC分类号： G01N24/08 ,  G01R33/46

摘要： This invention provides, among other things, methods for determining the average number of first polymers covalently attached to protein-first polymer conjugates in a solution.

公开(公告)号：US11603519B2

公开(公告)日：2023-03-14

申请号：US16483876

申请日：2018-02-05

申请人： National Cancer Center Japan ,  Kyoto University ,  Takeda Pharmaceutical Company Limited

发明人： Tetsuya Nakatsura ,  Toshiaki Yoshikawa ,  Yasushi Uemura ,  Kyoko Fukuda ,  Shin Kaneko ,  Atsutaka Minagawa ,  Yoshiaki Kassai ,  Atsushi Matsuda

IPC分类号： C12N5/0783 ,  A61P35/00 ,  A61K35/17 ,  C07K14/725 ,  C12N15/86

摘要： Provided is a T cell receptor capable of binding to a peptide having the amino acid sequence shown in SEQ ID NO: 27 or a complex of the peptide and HLA-A24. A T cell receptor capable of binding to a peptide having the amino acid sequence shown in SEQ ID NO: 28 or a complex of the peptide and HLA-A02. Disclosed T cell receptors are useful in treating or avoiding cancers which are associated with expression of glypican-3.

公开(公告)号：US11597928B2

公开(公告)日：2023-03-07

申请号：US16980191

申请日：2019-03-13

申请人： National University Corporation Tokyo Medical and Dental University ,  Takeda Pharmaceutical Company Limited

发明人： Takanori Yokota ,  Tetsuya Nagata ,  Hideki Furukawa ,  Yasuo Nakagawa ,  Takatoshi Yogo ,  Ryosuke Tokunoh ,  Shigekazu Sasaki ,  Kosuke Hidaka ,  Tomohiro Seki ,  Kenichi Miyata ,  Akio Uchida

IPC分类号： C07H21/04 ,  C12N15/113 ,  A61P25/00

摘要： Developed and provided is: a nucleic acid agent that is efficiently delivered to the central nervous system, to which drug delivery is inhibited by the blood brain barrier mechanism, and that provides an antisense effect to a target transcription product at the delivery site; and a composition containing such a nucleic acid agent.
Provided is a double-stranded nucleic acid complex consisting of a first nucleic acid strand and a second nucleic acid strand that are annealed to each other; wherein the first nucleic acid strand hybridizes with part of a target transcription product and has an antisense effect on the target transcription product; and wherein the second nucleic acid strand includes a base sequence complementary to the first nucleic acid strand and is conjugated to a phosphatidylethanolamine or an analog thereof.

公开(公告)号：US11583526B2

公开(公告)日：2023-02-21

申请号：US16998900

申请日：2020-08-20

申请人： Myovant Sciences GmbH ,  Takeda Pharmaceutical Company Limited

发明人： Vijaykumar Reddy Rajasekhar ,  Brendan Mark Johnson ,  David B. MacLean ,  Lynn Seely ,  Paul N. Mudd, Jr.

IPC分类号： A61K31/517 ,  A61K31/4164 ,  A61P35/00 ,  A61K31/501 ,  A61K31/513 ,  A61K9/00 ,  A61K31/4166

摘要： Methods for treating prostate cancer, including advanced prostate cancer, in a subject in need thereof, include administering once-daily to the subject, at least 80 mg of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N′-methoxyurea, or a corresponding amount of a pharmaceutically acceptable salt thereof. Another method includes: administering once-daily to the subject in need thereof, an oral load dose formulation having from 240 mg to 480 mg of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N′-methoxyurea, or a corresponding amount of a pharmaceutically acceptable salt thereof; and thereafter administering once-daily to the subject, an oral maintenance dose formulation having 80 mg to 160 mg of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N′-methoxyurea, or a corresponding amount of a pharmaceutically acceptable salt thereof.

公开(公告)号：US20230028114A1

公开(公告)日：2023-01-26

申请号：US17753803

申请日：2020-09-15

申请人： Holger MONENSCHEIN ,  Sean MURPHY ,  Scott OLSEN ,  Natasha O'ROURKE ,  Holly REICHARD ,  Melinda DAVIS ,  Betty LAM ,  TAKEDA PHARMACEUTICAL COMPANY LIMITED

发明人： Holger MONENSCHEIN ,  Sean MURPHY ,  Scott OLSEN ,  Natasha O'ROURKE ,  Holly REICHARD ,  Melinda DAVIS ,  Betty LAM

IPC分类号： A61K31/5025 ,  C07D471/04

摘要： Disclosed are compounds of Formula (1) and pharmaceutically acceptable salts thereof, wherein α, β, n, R4, R5, R6, R8, R9, R10, R11, X1, X2, X3 and X7 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula (1), to pharmaceutical compositions comprising them, and to their use for treating diseases, disorders, and conditions associated with GPR139.

公开(公告)号：US11560372B2

公开(公告)日：2023-01-24

申请号：US16606043

申请日：2018-04-17

申请人： TAKEDA PHARMACEUTICAL COMPANY LIMITED

发明人： Shinobu Sasaki ,  Masaki Seto ,  Kazuaki Takami ,  Haruhi Ando

IPC分类号： C07D405/14 ,  A61P1/10 ,  C07D405/04 ,  C07D409/14

摘要： The present invention aims to provide a compound that may be useful for the prophylaxis or treatment of constipation and the like. The present invention provides a compound represented by the following formula (I): wherein each symbol is as described in the specification, salt thereof.

公开(公告)号：US20230000915A1

公开(公告)日：2023-01-05

申请号：US17778611

申请日：2020-11-24

申请人： Kyoto University ,  Takeda Pharmaceutical Company Limited

发明人： Shin KANEKO ,  Suguru ARIMA ,  Maiko TAKIGUCHI ,  Yoshiaki KASSAI ,  Akira HAYASHI

IPC分类号： A61K35/17 ,  C12N5/0783 ,  C12N15/62 ,  C12N15/86 ,  C07K14/725 ,  C07K14/705 ,  A61P35/00

摘要： The present invention provides a system for providing a T cell product, including a T cell master cell bank and/or a T cell working cell bank.